During its annual GPU Technology Conference, which kicked off with a virtual keynote today, Nvidia unveiled a slew of health care-related initiatives aimed at accelerating workloads in drug discovery, preventative medicine, and more. The company announced a partnership with GlaxoSmithKline (GSK) to help develop an AI-powered lab for vaccine and treatment discovery. Nvidia also detailed an AI model built in collaboration with Massachusetts General Brigham Hospital to predict the oxygen needs of emergency room patients with COVID-19 symptoms. And the company revealed it will contribute hardware and expertise to what is expected to be the U.K.’s fastest supercomputer, Cambridge-1.
Cambridge-1, which Nvidia expects to come online by year-end 2020, is a joint project between GSK, AstraZeneca, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, and Oxford Nanopore. Built on Nvidia’s DGX SuperPOD architecture, it’s anticipated to deliver over 400 petaflops of AI performance and 8 petaflops of Linpack